Product Information
TAK-700 is a novel nonsteroidal antiandrogen that binds to the endothelin-A receptor. It has been shown to reduce the risk of prostate cancer, and also possess anti-inflammatory properties. TAK-700 was shown to inhibit the growth of granulosa cells in vitro and in vivo, which may be due to its ability to bind to and inhibit the activity of endothelin-A receptors. TAK-700 also inhibits enzyme activities such as polymerase chain reaction (PCR) and protein synthesis in prostate cancer cells. TAK-700 is being investigated for use in treating infectious diseases, such as hepatitis C virus infections, as well as other types of cancers that are associated with glucocorticoid receptor activation. The drug has been shown not to have any significant effects on adrenal function when administered at therapeutic doses.
Chemical properties
Technical inquiry about: 3D-BSA21918 TAK-700 (Orteronel)
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
